Anna Świerczek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Anna Świerczek has a total of 28 co-authors. Here are the top co-authors by number of shared publications:
- Aleksander Gajkowski
Samodzielny Publiczny Zespół Zakładów Opieki Zdrowotnej w Wyszkowie, Poland
9 shared publications - Bartosz Zawadzki
Independent Public Health Care Institution of the Ministry of the Interior and Administration, Krakow, Poland
9 shared publications - Krzysztof Bednarski
Beskid Oncology Center Municipal Hospital of John Paul II, Bielsko-Biała, Poland
9 shared publications - Miłosz Rewekant
Beskid Oncology Center Municipial Hospital of John Paul II, Bielsko - Biała, Poland
9 shared publications - Natalia Kornacka
Beskid Oncology Center Municipal Hospital of John Paul II, Bielsko-Biała, Poland
9 shared publications - Tomasz Adam Szczepanowski
Samodzielny Publiczny Centralny Szpital Kliniczny: Warsaw, Mazovia, PL
9 shared publications
Latest Publications
- Open Access
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
SYSTEMIC LUPUS ERYTHEMATOSUS – PAST, PRESENT AND EMERGING THERAPIES
Background Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by immune dysregulation, autoantibody production, and immune complex-mediated tissue damage. Despite advances in disease management, SLE remains associated with substantial morbidity, increased mortality, and significant therapeutic challenges. Objective This narrative review summarizes the current understanding of SLE epidemiology, pathogenesis, diagnosis, and treatment, with a particular focus on established therapeutic strategies and emerging treatment modalities. Methods A comprehensive literature search was conducted using publicly available scientific databases. Clinical guidelines, systematic reviews, meta-analyses, and original research articles were selected based on their relevance to SLE pathogenesis, diagnosis, and treatment. Results Current management of SLE aims to achieve remission or low disease activity through the use of hydroxychloroquine, glucocorticoids, conventional immunosuppressive agents, and targeted biologic therapies, including belimumab and anifrolumab. Improved understanding of SLE immunopathogenesis has facilitated the development of novel therapeutic approaches. Among these, hematopoietic stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy have demonstrated encouraging results in patients with severe or treatment-refractory disease. However, their widespread implementation is currently limited by safety concerns, treatment-related toxicity, high cost, limited clinical experience, and the absence of long-term efficacy and safety data. Conclusions Although recent therapeutic advances have improved clinical outcomes in SLE, many patients continue to experience refractory disease and treatment-related complications. Emerging therapies offer the potential for more targeted and durable disease control, but further large-scale clinical studies with extended follow-up are required to establish their long-term efficacy, safety, and place in future treatment algorithms.
- 22 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (3(51))
Open AccessSYSTEMIC LUPUS ERYTHEMATOSUS – PAST, PRESENT AND EMERGING THERAPIES
Background Systemic lupus erythematosus (SLE) is a chronic, multisystem autoimmune disease characterized by immune dysregulation, autoantibody production, and immune complex-mediated tissue damage. Despite advances in disease management, SLE remains associated with substantial morbidity, increased mortality, and significant therapeutic challenges. Objective This narrative review summarizes the current understanding of SLE epidemiology, pathogenesis, diagnosis, and treatment, with a particular focus on established therapeutic strategies and emerging treatment modalities. Methods A comprehensive literature search was conducted using publicly available scientific databases. Clinical guidelines, systematic reviews, meta-analyses, and original research articles were selected based on their relevance to SLE pathogenesis, diagnosis, and treatment. Results Current management of SLE aims to achieve remission or low disease activity through the use of hydroxychloroquine, glucocorticoids, conventional immunosuppressive agents, and targeted biologic therapies, including belimumab and anifrolumab. Improved understanding of SLE immunopathogenesis has facilitated the development of novel therapeutic approaches. Among these, hematopoietic stem cell transplantation and chimeric antigen receptor (CAR) T-cell therapy have demonstrated encouraging results in patients with severe or treatment-refractory disease. However, their widespread implementation is currently limited by safety concerns, treatment-related toxicity, high cost, limited clinical experience, and the absence of long-term efficacy and safety data. Conclusions Although recent therapeutic advances have improved clinical outcomes in SLE, many patients continue to experience refractory disease and treatment-related complications. Emerging therapies offer the potential for more targeted and durable disease control, but further large-scale clinical studies with extended follow-up are required to establish their long-term efficacy, safety, and place in future treatment algorithms.
- Open Access
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
VITAMIN D SUPPLEMENTATION IN BURN PATIENTS: EFFECTS ON WOUND HEALING AND CLINICAL OUTCOMES — A NARRATIVE REVIEW
Background: Burn injury induces profound metabolic, endocrine, and immunologic disturbances associated with impaired wound healing, increased infection risk, and prolonged recovery. Vitamin D deficiency is highly prevalent in patients with moderate-to-severe burns due to impaired cutaneous synthesis and altered metabolism. Objective: This narrative review summarizes current evidence regarding vitamin D deficiency and supplementation in burn patients, with emphasis on wound healing, infectious complications, and clinical outcomes. Methodology: A literature review was conducted using PubMed, Scopus, Web of Science, and Google Scholar databases. Clinical trials, observational studies, reviews, and meta-analyses published primarily between 2000 and 2025 were evaluated. Results: Available evidence demonstrated that vitamin D deficiency is common in burns involving ≥20% total body surface area and is associated with delayed wound healing, increased infectious complications, prolonged ICU and hospital stay, and long-term musculoskeletal abnormalities. Conclusion: Vitamin D appears to contribute to wound repair, immune modulation, and systemic recovery after burn injury; however, standardized burn-specific supplementation protocols remain unavailable.
- 7 September 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 3 (3(51))
Open AccessVITAMIN D SUPPLEMENTATION IN BURN PATIENTS: EFFECTS ON WOUND HEALING AND CLINICAL OUTCOMES — A NARRATIVE REVIEW
Background: Burn injury induces profound metabolic, endocrine, and immunologic disturbances associated with impaired wound healing, increased infection risk, and prolonged recovery. Vitamin D deficiency is highly prevalent in patients with moderate-to-severe burns due to impaired cutaneous synthesis and altered metabolism. Objective: This narrative review summarizes current evidence regarding vitamin D deficiency and supplementation in burn patients, with emphasis on wound healing, infectious complications, and clinical outcomes. Methodology: A literature review was conducted using PubMed, Scopus, Web of Science, and Google Scholar databases. Clinical trials, observational studies, reviews, and meta-analyses published primarily between 2000 and 2025 were evaluated. Results: Available evidence demonstrated that vitamin D deficiency is common in burns involving ≥20% total body surface area and is associated with delayed wound healing, increased infectious complications, prolonged ICU and hospital stay, and long-term musculoskeletal abnormalities. Conclusion: Vitamin D appears to contribute to wound repair, immune modulation, and systemic recovery after burn injury; however, standardized burn-specific supplementation protocols remain unavailable.
- Open Access
- 11 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 68, 74364
Hyaluronic Acid Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Literature Review
Background: Knee osteoarthritis (KOA) is a prevalent chronic degenerative condition and a leading cause of global disability. Intra-articular injections, specifically Hyaluronic Acid (HA) and Platelet-Rich Plasma (PRP), serve as critical non-surgical interventions when standard conservative therapies fail. Despite their widespread use, there is no universal consensus on which modality offers superior clinical outcomes. Aim: This literature review aims to systematically evaluate and synthesize current evidence from 2020 to 2026 comparing the efficacy and safety of intra-articular HA versus PRP for the treatment of knee osteoarthritis. Methodology: A review was conducted using the PubMed database, focusing on peer-reviewed literature from recent meta-analyses, systematic reviews, and randomized controlled trials published between 2020 and 2026. Results: The findings indicate that while both HA and PRP are safe and effective in the short term (1–3 months), PRP demonstrates statistically and clinically superior results in terms of pain reduction and functional improvement at mid-to-long-term follow-ups (6–12 months). Long-term studies suggest that PRP provides a more sustained therapeutic effect, with significantly higher joint survival rates compared to HA over 7 years. Furthermore, emerging evidence identifies PRP+HA combination therapy as a potentially optimal strategy, ranking highest for long-term efficacy by leveraging both mechanical lubrication and biological modulation. Both treatments maintain comparable safety profiles, characterized primarily by transient, local adverse events. Conclusion: PRP represents a superior conservative treatment for mild-to-moderate KOA compared to HA, particularly for patients seeking durable symptomatic relief. For clinical practice, PRP or combination therapy is recommended to achieve optimal long-term outcomes and potentially delay the progression toward invasive surgical interventions.
- 11 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 68, 74364
Open AccessHyaluronic Acid Versus Platelet-Rich Plasma for the Treatment of Knee Osteoarthritis: A Literature Review
Background: Knee osteoarthritis (KOA) is a prevalent chronic degenerative condition and a leading cause of global disability. Intra-articular injections, specifically Hyaluronic Acid (HA) and Platelet-Rich Plasma (PRP), serve as critical non-surgical interventions when standard conservative therapies fail. Despite their widespread use, there is no universal consensus on which modality offers superior clinical outcomes. Aim: This literature review aims to systematically evaluate and synthesize current evidence from 2020 to 2026 comparing the efficacy and safety of intra-articular HA versus PRP for the treatment of knee osteoarthritis. Methodology: A review was conducted using the PubMed database, focusing on peer-reviewed literature from recent meta-analyses, systematic reviews, and randomized controlled trials published between 2020 and 2026. Results: The findings indicate that while both HA and PRP are safe and effective in the short term (1–3 months), PRP demonstrates statistically and clinically superior results in terms of pain reduction and functional improvement at mid-to-long-term follow-ups (6–12 months). Long-term studies suggest that PRP provides a more sustained therapeutic effect, with significantly higher joint survival rates compared to HA over 7 years. Furthermore, emerging evidence identifies PRP+HA combination therapy as a potentially optimal strategy, ranking highest for long-term efficacy by leveraging both mechanical lubrication and biological modulation. Both treatments maintain comparable safety profiles, characterized primarily by transient, local adverse events. Conclusion: PRP represents a superior conservative treatment for mild-to-moderate KOA compared to HA, particularly for patients seeking durable symptomatic relief. For clinical practice, PRP or combination therapy is recommended to achieve optimal long-term outcomes and potentially delay the progression toward invasive surgical interventions.
- Open Access
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 66, 73870
GLP-1 RAs and Muscle Function Outcomes in Active Adults and Athletes
Background:Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a rapidly expanding pharmacological class used in the management of obesity and type 2 diabetes mellitus. Although prior reviews have documented their effects on body composition and skeletal muscle mass, functional outcomes including muscle strength, gait performance, and cardiorespiratory fitness in physically active adults and recreational athletes remain insufficiently characterised. Objective: To systematically review and critically appraise current clinical evidence regarding the effects of GLP-1 RA therapy on muscle function outcomes — specifically handgrip strength, gait speed, and VO2max — in physically active adults and recreational athletes. Methods: A narrative review of peer-reviewed literature published between 2019 and 2026 was performed using PubMed, EMBASE, and Cochrane databases. Results: GLP-1 RAs consistently reduce skeletal muscle mass; however, functional outcomes show a more heterogeneous pattern. Handgrip strength is generally preserved or modestly reduced, gait speed remains largely unaffected, and VO2max may improve with concomitant exercise training. The physically active population is underrepresented in existing trials. Conclusions: GLP-1 RA therapy does not uniformly impair muscle function in physically active individuals. Exercise prescription should be integrated with pharmacotherapy to optimise functional outcomes. Further dedicated RCTs in athletic populations are warranted.
- 8 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 66, 73870
Open AccessGLP-1 RAs and Muscle Function Outcomes in Active Adults and Athletes
Background:Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) represent a rapidly expanding pharmacological class used in the management of obesity and type 2 diabetes mellitus. Although prior reviews have documented their effects on body composition and skeletal muscle mass, functional outcomes including muscle strength, gait performance, and cardiorespiratory fitness in physically active adults and recreational athletes remain insufficiently characterised. Objective: To systematically review and critically appraise current clinical evidence regarding the effects of GLP-1 RA therapy on muscle function outcomes — specifically handgrip strength, gait speed, and VO2max — in physically active adults and recreational athletes. Methods: A narrative review of peer-reviewed literature published between 2019 and 2026 was performed using PubMed, EMBASE, and Cochrane databases. Results: GLP-1 RAs consistently reduce skeletal muscle mass; however, functional outcomes show a more heterogeneous pattern. Handgrip strength is generally preserved or modestly reduced, gait speed remains largely unaffected, and VO2max may improve with concomitant exercise training. The physically active population is underrepresented in existing trials. Conclusions: GLP-1 RA therapy does not uniformly impair muscle function in physically active individuals. Exercise prescription should be integrated with pharmacotherapy to optimise functional outcomes. Further dedicated RCTs in athletic populations are warranted.
- Open Access
- 6 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 65
The High Altitude Sickness - Epidemiology, Pathophysiology, Symptoms, Prevention and Treatment
High altitude sickness encompasses three overlapping syndromes—acute mountain sickness (AMS), high altitude cerebral edema (HACE), and high altitude pulmonary edema (HAPE)—triggered when ascent outpaces acclimatization to hypobaric hypoxia. With more than 100 million people ascending above 2,500 m annually, these conditions represent a significant yet largely preventable burden in travel medicine. This narrative review synthesizes current evidence on the epidemiology, pathophysiology, clinical presentation, prevention, and treatment of acute altitude illness. Relevant literature was identified through PubMed/MEDLINE and Google Scholar, prioritizing recent authoritative syntheses, Cochrane systematic reviews of preventive interventions, consensus diagnostic statements, and primary mechanistic studies. No formal quality scoring or meta-analysis was performed. AMS is the most common form, with prevalence ranging from 15% to 80% depending on absolute altitude, ascent rate, and individual susceptibility; prior history is the strongest predictor. HACE and HAPE are rarer but potentially fatal, the latter being the leading cause of altitude-related death. All forms originate from hypobaric hypoxia: the cerebral syndromes reflect hypoxic vasodilation and blood-brain barrier disruption with vasogenic edema, whereas HAPE arises from exaggerated, heterogeneous hypoxic pulmonary vasoconstriction causing capillary stress failure. Emerging research highlights roles for HIF and VEGF signaling, oxidative stress, and microglial activation. Prevention rests on graded ascent—particularly controlling nightly gains in sleeping altitude—supplemented by acetazolamide, dexamethasone, or nifedipine in higher-risk individuals. Treatment is anchored by descent, complemented by oxygen and targeted pharmacotherapy. Early recognition of ataxia and resting dyspnea remains the single most important determinant of survival.
- 6 August 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 65
Open AccessThe High Altitude Sickness - Epidemiology, Pathophysiology, Symptoms, Prevention and Treatment
High altitude sickness encompasses three overlapping syndromes—acute mountain sickness (AMS), high altitude cerebral edema (HACE), and high altitude pulmonary edema (HAPE)—triggered when ascent outpaces acclimatization to hypobaric hypoxia. With more than 100 million people ascending above 2,500 m annually, these conditions represent a significant yet largely preventable burden in travel medicine. This narrative review synthesizes current evidence on the epidemiology, pathophysiology, clinical presentation, prevention, and treatment of acute altitude illness. Relevant literature was identified through PubMed/MEDLINE and Google Scholar, prioritizing recent authoritative syntheses, Cochrane systematic reviews of preventive interventions, consensus diagnostic statements, and primary mechanistic studies. No formal quality scoring or meta-analysis was performed. AMS is the most common form, with prevalence ranging from 15% to 80% depending on absolute altitude, ascent rate, and individual susceptibility; prior history is the strongest predictor. HACE and HAPE are rarer but potentially fatal, the latter being the leading cause of altitude-related death. All forms originate from hypobaric hypoxia: the cerebral syndromes reflect hypoxic vasodilation and blood-brain barrier disruption with vasogenic edema, whereas HAPE arises from exaggerated, heterogeneous hypoxic pulmonary vasoconstriction causing capillary stress failure. Emerging research highlights roles for HIF and VEGF signaling, oxidative stress, and microglial activation. Prevention rests on graded ascent—particularly controlling nightly gains in sleeping altitude—supplemented by acetazolamide, dexamethasone, or nifedipine in higher-risk individuals. Treatment is anchored by descent, complemented by oxygen and targeted pharmacotherapy. Early recognition of ataxia and resting dyspnea remains the single most important determinant of survival.
- Open Access
- 7 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73181
Role of Antipsychotic Agents in Dementia-Associated Neuropsychiatric Symptoms: Efficacy, Safety, and Deprescribing Strategies
Background. Dementia syndromes involve cognitive and functional decline and frequent neuropsychiatric symptoms, including agitation, aggression, and hallucinations. These symptoms increase caregiver burden, institutionalization, and loss of quality of life. Antipsychotics remain relevant but controversial because benefits are modest and risks substantial. Aim. This review summarizes evidence and guideline recommendations on the role, indications, monitoring and deprescribing of antipsychotics in dementia-related neuropsychiatric symptoms. Material and methods. This narrative review was based on selected guidelines, systematic reviews, network meta-analyses, randomized trials and observational studies on antipsychotic use in dementia-related neuropsychiatric symptoms Results. Antipsychotics should not be routine first-line treatment. Before pharmacotherapy, reversible causes such as pain, delirium, infection, dehydration, drug effects and environmental triggers should be assessed. Psychosocial and environmental interventions remain fundamental. Antipsychotics may be considered only in selected patients with severe agitation, aggression or psychosis causing distress or risk of harm. Evidence supports modest efficacy mainly for agitation and aggression, whereas effects on psychosis are less consistent. Risperidone is a well-established option for severe aggression and agitation in Alzheimer’s disease, while brexpiprazole has emerged as an option for agitation in Alzheimer’s dementia. Treatment requires individualized risk-benefit assessment because of sedation, extrapyramidal symptoms, falls, cerebrovascular events, pneumonia, acute kidney injury, thromboembolism and mortality. Conclusions. Antipsychotics have a restricted but important role in dementia care. Their use should be symptom-targeted, time-limited, monitored and linked to deprescribing.
- 7 July 2026
- Published by Uniwersytet Mikolaja Kopernika/Nicolaus Copernicus University in Quality in Sport
- Vol. 61, 73181
Open AccessRole of Antipsychotic Agents in Dementia-Associated Neuropsychiatric Symptoms: Efficacy, Safety, and Deprescribing Strategies
Background. Dementia syndromes involve cognitive and functional decline and frequent neuropsychiatric symptoms, including agitation, aggression, and hallucinations. These symptoms increase caregiver burden, institutionalization, and loss of quality of life. Antipsychotics remain relevant but controversial because benefits are modest and risks substantial. Aim. This review summarizes evidence and guideline recommendations on the role, indications, monitoring and deprescribing of antipsychotics in dementia-related neuropsychiatric symptoms. Material and methods. This narrative review was based on selected guidelines, systematic reviews, network meta-analyses, randomized trials and observational studies on antipsychotic use in dementia-related neuropsychiatric symptoms Results. Antipsychotics should not be routine first-line treatment. Before pharmacotherapy, reversible causes such as pain, delirium, infection, dehydration, drug effects and environmental triggers should be assessed. Psychosocial and environmental interventions remain fundamental. Antipsychotics may be considered only in selected patients with severe agitation, aggression or psychosis causing distress or risk of harm. Evidence supports modest efficacy mainly for agitation and aggression, whereas effects on psychosis are less consistent. Risperidone is a well-established option for severe aggression and agitation in Alzheimer’s disease, while brexpiprazole has emerged as an option for agitation in Alzheimer’s dementia. Treatment requires individualized risk-benefit assessment because of sedation, extrapyramidal symptoms, falls, cerebrovascular events, pneumonia, acute kidney injury, thromboembolism and mortality. Conclusions. Antipsychotics have a restricted but important role in dementia care. Their use should be symptom-targeted, time-limited, monitored and linked to deprescribing.
- Open Access
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
CURRENT DIAGNOSTIC AND THERAPEUTIC APPROACHES TO PERIPROSTHETIC JOINT INFECTION: A NARRATIVE REVIEW
Background: Periprosthetic joint infection (PJI) remains one of the most serious complications after total hip and knee arthroplasty. Although its incidence after primary arthroplasty is relatively low, PJI causes major morbidity, repeated surgery, prolonged antimicrobial treatment, impaired function, and substantial healthcare costs. Diagnosis is difficult because clinical findings may be nonspecific, particularly in chronic low-grade infection, and no single test reliably confirms or excludes infection in all clinical settings. Objective: This narrative review summarizes contemporary diagnostic approaches to PJI and discusses current therapeutic strategies in relation to major definitions, guidelines, and recent evidence. Methodology: PubMed, Google Scholar, and the Cochrane Library were searched for English-language publications on hip and knee PJI, with emphasis on consensus definitions, diagnostic criteria, synovial biomarkers, microbiological and molecular diagnostics, imaging, surgical treatment, antimicrobial therapy, and suppressive treatment. The search was updated through March 2026. Results: Current diagnosis relies on multimodal assessment integrating clinical findings, serum inflammatory markers, synovial fluid analysis, microbiology, histopathology, and selected imaging studies. The 2018 ICM/MSIS criteria and the 2021 EBJIS definition remain the most influential frameworks. Treatment is primarily surgical and includes DAIR, one-stage revision, and two-stage revision supported by targeted antimicrobial therapy. Conclusion: Effective PJI management requires individualized multidisciplinary decision-making. Emerging biomarkers, molecular methods, artificial intelligence, and antibacterial implant technologies are promising but require further validation before routine implementation.
- 2 July 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 1 (3(51))
Open AccessCURRENT DIAGNOSTIC AND THERAPEUTIC APPROACHES TO PERIPROSTHETIC JOINT INFECTION: A NARRATIVE REVIEW
Background: Periprosthetic joint infection (PJI) remains one of the most serious complications after total hip and knee arthroplasty. Although its incidence after primary arthroplasty is relatively low, PJI causes major morbidity, repeated surgery, prolonged antimicrobial treatment, impaired function, and substantial healthcare costs. Diagnosis is difficult because clinical findings may be nonspecific, particularly in chronic low-grade infection, and no single test reliably confirms or excludes infection in all clinical settings. Objective: This narrative review summarizes contemporary diagnostic approaches to PJI and discusses current therapeutic strategies in relation to major definitions, guidelines, and recent evidence. Methodology: PubMed, Google Scholar, and the Cochrane Library were searched for English-language publications on hip and knee PJI, with emphasis on consensus definitions, diagnostic criteria, synovial biomarkers, microbiological and molecular diagnostics, imaging, surgical treatment, antimicrobial therapy, and suppressive treatment. The search was updated through March 2026. Results: Current diagnosis relies on multimodal assessment integrating clinical findings, serum inflammatory markers, synovial fluid analysis, microbiology, histopathology, and selected imaging studies. The 2018 ICM/MSIS criteria and the 2021 EBJIS definition remain the most influential frameworks. Treatment is primarily surgical and includes DAIR, one-stage revision, and two-stage revision supported by targeted antimicrobial therapy. Conclusion: Effective PJI management requires individualized multidisciplinary decision-making. Emerging biomarkers, molecular methods, artificial intelligence, and antibacterial implant technologies are promising but require further validation before routine implementation.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
INNOVATIVE THERAPEUTIC STRATEGIES IN AGE-RELATED MACULAR DEGENERATION: CURRENT AND FUTURE PERSPECTIVES
Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in older adults and an increasing public health challenge. Its pathogenesis involves oxidative stress, chronic inflammation, complement dysregulation, retinal pigment epithelium dysfunction, and pathological angiogenesis. This narrative review summarizes current and emerging therapeutic strategies for AMD, focusing on innovative technologies, durable drug-delivery systems, precision medicine, and artificial intelligence (AI). A literature search was conducted using PubMed, Cochrane Library, Google Scholar, and selected clinical guidelines. Randomized clinical trials, phase 1–3 studies, review articles, translational research, and current recommendations published mainly between 2018 and 2026 were included. Anti-VEGF therapy remains the standard treatment for neovascular AMD, while faricimab enables extended dosing through dual VEGF-A and angiopoietin-2 inhibition. In geographic atrophy, pegcetacoplan and avacincaptad pegol represent the first disease-modifying therapies by slowing lesion progression. Gene therapy, cell-based approaches, the Port Delivery System, nanotechnology, biomarkers, and AI-assisted imaging may further reduce treatment burden and support personalized retinal care. Current AMD management is shifting toward longer-acting, mechanism-based, and technology-supported strategies, although further studies are required to confirm their long-term safety, accessibility, cost-effectiveness, and real-world clinical value.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessINNOVATIVE THERAPEUTIC STRATEGIES IN AGE-RELATED MACULAR DEGENERATION: CURRENT AND FUTURE PERSPECTIVES
Age-related macular degeneration (AMD) is a leading cause of irreversible central vision loss in older adults and an increasing public health challenge. Its pathogenesis involves oxidative stress, chronic inflammation, complement dysregulation, retinal pigment epithelium dysfunction, and pathological angiogenesis. This narrative review summarizes current and emerging therapeutic strategies for AMD, focusing on innovative technologies, durable drug-delivery systems, precision medicine, and artificial intelligence (AI). A literature search was conducted using PubMed, Cochrane Library, Google Scholar, and selected clinical guidelines. Randomized clinical trials, phase 1–3 studies, review articles, translational research, and current recommendations published mainly between 2018 and 2026 were included. Anti-VEGF therapy remains the standard treatment for neovascular AMD, while faricimab enables extended dosing through dual VEGF-A and angiopoietin-2 inhibition. In geographic atrophy, pegcetacoplan and avacincaptad pegol represent the first disease-modifying therapies by slowing lesion progression. Gene therapy, cell-based approaches, the Port Delivery System, nanotechnology, biomarkers, and AI-assisted imaging may further reduce treatment burden and support personalized retinal care. Current AMD management is shifting toward longer-acting, mechanism-based, and technology-supported strategies, although further studies are required to confirm their long-term safety, accessibility, cost-effectiveness, and real-world clinical value.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
FROM INFECTION TO DYSBIOSIS: PATHOGENESIS OF POST-INFECTIOUS IRRITABLE BOWEL SYNDROME - DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS
Introduction: Post-infectious irritable bowel syndrome (PI-IBS) develops in approximately 14.5% of individuals after acute gastroenteritis and persists long-term, with emerging evidence suggesting an autoimmune component linking infection to chronic gastrointestinal dysfunction. This review aims to synthesize current literature on the proposed pathogenesis of PI-IBS, focusing on molecular mechanisms, the development of small intestinal bacterial overgrowth (SIBO), and resulting diagnostic and therapeutic implications. Materials and methods: A narrative review of PubMed literature was performed, focusing on autoantibody-mediated disruption of gut motility, candidate diagnostic biomarkers, and emerging therapeutic approaches. Studies were selected based on relevance and methodological quality, without formal inclusion or exclusion criteria. Results: Infection by cytolethal distending toxin (CDT)-producing bacteria triggers anti-CdtB antibody production, which through molecular mimicry may cross-react with human vinculin in the interstitial cells of Cajal, causing enteric neuropathy and impaired migrating motor complex function. The resulting dysmotility may facilitate SIBO development. Combined anti-CdtB and anti-vinculin serum biomarkers can offer post-test probability exceeding 98% for diarrhea-predominant IBS. Antibody-depleting therapies, such as plasmapheresis and intravenous immunoglobulin, may reduce autoantibody burden and correlate with symptomatic improvement. Conclusions: PI-IBS may represent an immune-mediated consequence of acute bacterial gastroenteritis, in which CdtB-induced autoimmunity drives dysmotility and microbial dysbiosis. This mechanistic framework offers potential biomarkers and therapeutic targets. Further prospective studies are needed to validate these findings.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 5 (2(50))
Open AccessFROM INFECTION TO DYSBIOSIS: PATHOGENESIS OF POST-INFECTIOUS IRRITABLE BOWEL SYNDROME - DIAGNOSTIC AND THERAPEUTIC IMPLICATIONS
Introduction: Post-infectious irritable bowel syndrome (PI-IBS) develops in approximately 14.5% of individuals after acute gastroenteritis and persists long-term, with emerging evidence suggesting an autoimmune component linking infection to chronic gastrointestinal dysfunction. This review aims to synthesize current literature on the proposed pathogenesis of PI-IBS, focusing on molecular mechanisms, the development of small intestinal bacterial overgrowth (SIBO), and resulting diagnostic and therapeutic implications. Materials and methods: A narrative review of PubMed literature was performed, focusing on autoantibody-mediated disruption of gut motility, candidate diagnostic biomarkers, and emerging therapeutic approaches. Studies were selected based on relevance and methodological quality, without formal inclusion or exclusion criteria. Results: Infection by cytolethal distending toxin (CDT)-producing bacteria triggers anti-CdtB antibody production, which through molecular mimicry may cross-react with human vinculin in the interstitial cells of Cajal, causing enteric neuropathy and impaired migrating motor complex function. The resulting dysmotility may facilitate SIBO development. Combined anti-CdtB and anti-vinculin serum biomarkers can offer post-test probability exceeding 98% for diarrhea-predominant IBS. Antibody-depleting therapies, such as plasmapheresis and intravenous immunoglobulin, may reduce autoantibody burden and correlate with symptomatic improvement. Conclusions: PI-IBS may represent an immune-mediated consequence of acute bacterial gastroenteritis, in which CdtB-induced autoimmunity drives dysmotility and microbial dysbiosis. This mechanistic framework offers potential biomarkers and therapeutic targets. Further prospective studies are needed to validate these findings.
- Open Access
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
TRANSVERSE TIBIAL BONE TRANSFER (TTBT) IN DIABETIC FOOT ULCER (DFU): TECHNICAL ASPECTS, BIOCHEMICAL MECHANISMS, SAFETY AND OUTCOMES OF A NOVEL SURGICAL METHOD
Background. Diabetic foot ulcers (DFUs) affect a substantial proportion of the 589 million adults currently living with diabetes worldwide and remain a leading cause of lower-limb amputation and excess mortality. Despite debridement, offloading, advanced dressings, negative-pressure wound therapy, hyperbaric oxygen, topical growth factors, and revascularisation, recalcitrant ulcers still progress to amputation in approximately 20% of cases, with five-year mortality near 70% among those amputated. Tibial cortex transverse transport (TTT), a derivative of Ilizarov’s distraction osteogenesis principle, has emerged as a regenerative surgical option for advanced DFUs. Methods. We performed a narrative review of literature published between January 2001 and April 2026, identified through PubMed and Google Scholar, addressing surgical technique, biological mechanisms, clinical efficacy, and safety of TTT in DFU. Results. TTT, a small antero-medial tibial corticotomy with slow transverse distraction, elicits a coordinated regenerative response. Mechanistic studies show distraction-induced elevation of proangiogenic mediators and satisfactory outcomes in patients. Clinical data, including a meta-analysis, a multicentre cohort and other small studies, indicate wound healing rates of approximately 95%, limb salvage rates exceeding 95%, and recurrence rates near 3% during two-year follow-up. Significant improvements in ankle-brachial index, dorsal foot temperature, pain scores, and quality of life are consistently reported. Complications are manageable: risks of approximately 2% for tibial fracture and 8% for pin-site infection. Conclusions. TTT is a mechanistically rich, clinically effective, and reasonably safe option for advanced DFUs. Adequately powered multicentre randomised trials comparing TTT with contemporary best practice are needed to define its definitive role.
- 30 June 2026
- Published by RS Global Sp. z O.O. in International Journal of Innovative Technologies in Social Science
- Vol. 4 (2(50))
Open AccessTRANSVERSE TIBIAL BONE TRANSFER (TTBT) IN DIABETIC FOOT ULCER (DFU): TECHNICAL ASPECTS, BIOCHEMICAL MECHANISMS, SAFETY AND OUTCOMES OF A NOVEL SURGICAL METHOD
Background. Diabetic foot ulcers (DFUs) affect a substantial proportion of the 589 million adults currently living with diabetes worldwide and remain a leading cause of lower-limb amputation and excess mortality. Despite debridement, offloading, advanced dressings, negative-pressure wound therapy, hyperbaric oxygen, topical growth factors, and revascularisation, recalcitrant ulcers still progress to amputation in approximately 20% of cases, with five-year mortality near 70% among those amputated. Tibial cortex transverse transport (TTT), a derivative of Ilizarov’s distraction osteogenesis principle, has emerged as a regenerative surgical option for advanced DFUs. Methods. We performed a narrative review of literature published between January 2001 and April 2026, identified through PubMed and Google Scholar, addressing surgical technique, biological mechanisms, clinical efficacy, and safety of TTT in DFU. Results. TTT, a small antero-medial tibial corticotomy with slow transverse distraction, elicits a coordinated regenerative response. Mechanistic studies show distraction-induced elevation of proangiogenic mediators and satisfactory outcomes in patients. Clinical data, including a meta-analysis, a multicentre cohort and other small studies, indicate wound healing rates of approximately 95%, limb salvage rates exceeding 95%, and recurrence rates near 3% during two-year follow-up. Significant improvements in ankle-brachial index, dorsal foot temperature, pain scores, and quality of life are consistently reported. Complications are manageable: risks of approximately 2% for tibial fracture and 8% for pin-site infection. Conclusions. TTT is a mechanistically rich, clinically effective, and reasonably safe option for advanced DFUs. Adequately powered multicentre randomised trials comparing TTT with contemporary best practice are needed to define its definitive role.